Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 409 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune System Disorder (Healthy Volunteer) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

NCT00344123
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir/Ritonavir, Rosuvastatin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

NCT02304185
View directory record Official record
Conditions
Healthy
Interventions
gp140, 50 mcg, gp140, 50 mcg + Adjuvant, gp140, 250 mcg, gp140, 250 mcg + Adjuvant, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jun 26, 2026, 1:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tissue Repository: CTCL Collection Protocol

NCT02840747
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Sézary Syndrome
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

NCT05203692
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Jun 26, 2026, 1:09 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

NCT05951816
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

NCT03949426
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Phase 1 Safety Study of Two Experimental HIV Vaccines

NCT00479999
View directory record Official record
Conditions
AIDS Vaccines, HIV Infections, HIV-1
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

NCT00936793
View directory record Official record
Conditions
HIV, Asthma
Interventions
Darunavir, Ritonavir, Beclomethasone Dipropionate HFA
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT04942964
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Bocidelpar
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction (DDI) Rifabutin

NCT02138084
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Rifabutin, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jun 26, 2026, 1:09 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

NCT06787586
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions
ATTO-1310, ATTO-1310 Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Encinitas, California • Rocklin, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 26, 2026, 1:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

NCT00899496
View directory record Official record
Conditions
Cancer
Interventions
immunological diagnostic method, physiologic testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

NCT03816696
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis

NCT06555562
View directory record Official record
Conditions
Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Ultrasound Stimulation, Non-active ultrasound stimulation
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
22 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs

NCT00005673
View directory record Official record
Conditions
Healthy, HIV Infection
Interventions
Capravirine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 1:09 PM EDT
Terminated Phase 1 Interventional

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

NCT00327080
View directory record Official record
Conditions
HIV
Interventions
MRI, L-NMMA, Acetylcholine
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

NCT05757856
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
NDX-3315, NDX-3324, SPECT/CT Imaging
Drug · Diagnostic Test
Lead sponsor
NexEos Diagnostics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

NCT05631704
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Midazolam, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918614
View directory record Official record
Conditions
Immune System Disorder (Healthy Volunteer)
Interventions
Belumosudil mesylate, Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

NCT07172321
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jun 26, 2026, 1:09 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of Treatments on Atopic Dermatitis

NCT01631617
View directory record Official record
Conditions
Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic, Skin Diseases
Interventions
Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline, Sodium hypochlorite, Placebo capsules, Placebo Sodium hypochlorite
Drug · Other
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 50 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

NCT01741493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ABT-494, Placebo, Tofacitinib
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Miami, Florida • Cincinnati, Ohio • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Jun 26, 2026, 1:09 PM EDT